drugset / Trial / NCT05856851

Intra-arterial Alteplase for Acute Ischemic Stroke After Mechanical Thrombectomy

NCT05856851 ↗

RandomizedParallel-groupSingle-blindTreatment

Summary

A multicenter, prospective, open-label, blinded endpoint, randomized controlled trial aiming at evaluating the efficacy and safety of intra-arterial recombinant human tissue plasminogen activator (rt-PA) after successful recanalization of acute large vessel occlusion in the anterior circulation by mechanical thrombectomy in improving the 90-day functional outcome.

Timeline

Start
2023-08-01
Primary completion
2025-12
Completion
2025-12

Outcome

Met primary endpoint

paper The proportion of patients with a modified Rankin Scale score of 0 or 1 at 90 days was 44.8% (73/163) in the intra-arterial alteplase group vs 30.2% (48/159) in the standard treatment group PMID 42262770 ↗

paper intra-arterial alteplase resulted in a higher likelihood of excellent outcomes at 90 days. PMID 42262770 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Alteplase Protein / enzyme biologic 0.225 mg/kg Other

Indications